Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chemo cocktail targets tough leukemias

NCT ID NCT02115295

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of four chemotherapy drugs—cladribine, idarubicin, cytarabine, and venetoclax—in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see if this mix can kill cancer cells more effectively and improve survival. The study is recruiting 508 participants at M.D. Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cladribine, idarubicin, cytarabine, and venetoclax (chemotherapy drugs)

What this could lead to

If successful, this combination could improve remission rates and survival for people with hard-to-treat blood cancers.

What could go wrong

This is a mid-stage trial, so results are not yet proven. Chemotherapy drugs have significant side effects, and the combination may not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute myeloid leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive myelodysplastic syndrome Myelodysplastic Syndromes therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE BIPHENOTYPIC LEUKEMIA ACUTE MYELOID LEUKEMIA BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE BLASTS 10 PERCENT OR MORE OF BONE MARROW NUCLEATED CELLS BLASTS 10 PERCENT OR MORE OF PERIPHERAL BLOOD WHITE CELLS DE NOVO MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC SYNDROME PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE SECONDARY ACUTE MYELOID LEUKEMIA UNTREATED ADULT ACUTE MYELOID LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-••••

    Contact